Gilles Ouvry Ph.D, appointed to newly created position of VP of Chemistry, based in Stevenage, UK Joins from Evotec, UK and brings 20 years of international medicinal chemistry experience including at Galderma, AstraZeneca and SCYNEXIS Will be responsible for developing NRG’s pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore […]

NRG Therapeutics Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, and Domainex Ltd., today announce a collaboration focused on developing novel small molecule disease-modifying medicines for the treatment of Parkinson’s disease, motor neurone disease (MND) and other debilitating chronic neurodegenerative disorders. Domainex, a leading integrated medicines research services partner, will provide fully integrated lead optimization […]

NRG’s second therapeutic programme to explore brain penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) as treatment for MND (ALS) Innovate UK EDGE grant enabled support from the Medicines Discovery Catapult Scientific and commercial insights gained will support MND clinical study design and Series A financing NRG Therapeutics Ltd (“NRG” or “company”), […]

NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, today announced further equity investment of £490k from Parkinson’s UK, to support the development of disease modifying drugs for the treatment of Parkinson’s. Following positive progress, this is the third investment Parkinson’s UK has made into NRG Therapeutics, bringing the total amount […]

Parkinson’s UK has invested an additional £1 million in NRG Therapeutics Ltd’s mitochondrial drug development programme. This funding boost, on top of an initial £1 million investment, will support the development of a breakthrough drug with the potential to slow or halt the progression of Parkinson’s – something no known treatment can currently do. Initiated […]